IDH1 and central nervous system cancer: For instance, the reduction of TET2 enzyme levels by promoter methylation in absence of TET2 mutation was reported recently in low-grade diffuse astrocytomas, suggesting that this represents an additional pathomechanism in IDH1- and IDH2-mutated low-grade gliomas [48].